Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink?
IDEXX Laboratories (IDXX), a global leader in animal health diagnostics, reported Q2 2026 revenue of $1.22B (up 9.7% YoY) and EPS of $4.07 (up 15.3%). The company raised its full-year outlook. Analysts have a 'Moderate Buy' consensus, with a mean price target of $718.14, suggesting 30.6% upside. IDXX stock is down 14.2% over 52 weeks, underperforming the S&P 500 and healthcare sector.
How this was made
The 30-second read
Why it matters
The earnings beat and raised outlook could trigger re‑rating by analysts and attract growth‑oriented investors.
Market read
Strong earnings and guidance lift IDXX and may boost related healthcare stocks.
What to watch
Potential supply‑chain constraints for reagents could temper growth.
Background
IDXX is a leading provider of veterinary diagnostic tools with a market cap of ~$50 B.
Ticker impact
IDXX reported Q2 2026 earnings, beating estimates and raised its full‑year 2026 outlook to $4.70‑$4.75 B revenue and $14.69‑$14.94 EPS.
Potential upside of 15‑25% if market prices in the higher guidance.
Guidance lift and strong cash flow exceed consensus, and analysts raised price targets, indicating bullish sentiment.
Market effects
Positive for the animal‑health diagnostics sector as IDXX leads market growth.
U.S. biotech and healthcare stocks may see modest gains.
Limited to investors tracking veterinary diagnostics worldwide.
Counterpoint
If guidance is overly optimistic, a pull‑back could occur on subsequent quarters.
Key entities
- AnalystBarclays
Raised price target to $710 after earnings.
